For eligible subject, tumor material will be tested by immunohistochemistry (Pan-Trk ICH testing with mAb EPR17341).

Tumor material tested positive will be analyzed by next-generation sequencing to identify NTRK1, NTRK2 or NTRK3 gene fusions.

Retrospective cohort

This retrospective study has a primary objective to estimate the incidence of NTRK gene fusion depending on the histological diagnosis.

This retrospective study has a primary objective to estimate the incidence of NTRK gene fusion depending on the histological diagnosis. The tropomyosin receptor kinase (Trk) receptor family comprises 3 transmembrane proteins referred to as Trk A, B and C (TrkA, TrkB and TrkC) receptors that are encoded by the NTRK1, NTRK2 and NTRK3 genes, respectively. These receptor tyrosine kinases are expressed in human neuronal tissue and play an essential role in the physiology of development and function of the nervous system through activation by neurotrophins. Gene fusions involving NTRK genes lead to transcription of chimeric Trk proteins with constitutively activated or overexpressed kinase function conferring oncogenic potential. These genetic abnormalities have recently emerged as targets for cancer therapy, because novel compounds have been developed that are selective inhibitors of the constitutively active rearranged proteins. Developments in this field are being aided by next generation sequencing methods as tools for unbiased gene fusions discovery. However, the incidence of NTRK aberrations in solid tumors is unknown as well as the natural history of NTRK-rearranged tumors This study will provide better knowledge of NTRK gene fusion incidence to allow recommendations for pathological diagnosis.

A Retrospective Study to Determine the Incidence of NTRK Fusions. NTRK Study

A Study to Determine the Incidence of NTRK Fusions in Subjects With Locally Advanced/Unresectable or Metastatic Solid Tumors With NTRK Fusions and Related Treatment Outcomes.

ORR will be defined as the proportion of patients with objective response (complete or partial response) during the first-line anti-cancer therapy.

PFS will be defined as the delay from the date of onset of first-line anti-cancer therapy to the date of progression.

OS will be defined as the delay from the date of start first-line anti-cancer therapy to the date of death (whatever the cause).

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
A Retrospective Study to Determine the Incidence of NTRK Fusions. NTRK Study	NCT04010240	Metastatic Soli...	Retrospective c...	1 Month -	Institut Bergonié
A Retrospective Study to Determine the Incidence of NTRK Fusions. NTRK Study	NCT04010240	Metastatic Soli...	Retrospective c...	1 Month -	Institut Bergonié

Spots Global Cancer Trial Database for retrospective cohort